피록시캄

3.06

3

23

1.43e-01 g/L

>49.7 [ug/mL] (The mean of the results at pH 7.4)

198-200 °C

198 - 200 °C

Solid; [Merck Index]

Solid

169.42 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；172.96 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；169.32 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

170.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

170.9 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Danger

H301 (99%): Toxic if swallowed [Danger Acute toxicity, oral]；H360 (16.6%): May damage fertility or the unborn child [Danger Reproductive toxicity]；H361 (17.6%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]；H372 (34.6%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]

P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 205 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

IMAP assessments - 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide: Environment tier I assessment；IMAP assessments - 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide: Human health tier I assessment

Can cause photo-allergic contact dermatitis; It can also induce systemic photo-sensitivity in patients sensitized to thiomersal. [Kanerva, p. 1827] Piroxicam may induce photosensitivity in patients taking it systemically (photodrug reaction). [Marks, p. 201-3]

M01AC01

M - Musculo-skeletal system；M01 - Antiinflammatory and antirheumatic products；M01A - Antiinflammatory and antirheumatic products, non-steroids；M01AC - Oxicams；M01AC01 - Piroxicam

S - Sensory organs；S01 - Ophthalmologicals；S01B - Antiinflammatory agents；S01BC - Antiinflammatory agents, non-steroids；S01BC06 - Piroxicam

M - Musculo-skeletal system；M02 - Topical products for joint and muscular pain；M02A - Topical products for joint and muscular pain；M02AA - Antiinflammatory preparations, non-steroids for topical use；M02AA07 - Piroxicam

QM - Musculo-skeletal system；QM01 - Antiinflammatory and antirheumatic products；QM01A - Antiinflammatory and antirheumatic products, non-steroids；QM01AC - Oxicams；QM01AC01 - Piroxicam

QM - Musculo-skeletal system；QM02 - Topical products for joint and muscular pain；QM02A - Topical products for joint and muscular pain；QM02AA - Antiinflammatory preparations, non-steroids for topical use；QM02AA07 - Piroxicam

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.

Renal

Piroxicam has known human metabolites that include 5'-Hydroxypiroxicam.